Navigation Links
Biodel Reports Top-Line Results From Pump Study of Experimental Insulins
Date:9/27/2011

DANBURY, Conn., Sept. 27, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced top-line results from a Phase 1 clinical trial of BIOD-105 and BIOD-107 at Oregon Health and Sciences University to evaluate the pharmacokinetic, pharmacodynamic and infusion site tolerability profiles of these ultra-rapid-acting formulations of recombinant human insulin, relative to Humalog®, when delivered by insulin pumps.    

The trial was a single-center, randomized, double-blind, three-period crossover trial in 8 subjects with Type 1 diabetes.  Each study drug was administered on separate days.  Pharmacodynamics were assessed using the euglycemic clamp method.  Local infusion site discomfort was measured with a 100 mm visual analog scale and patient questionnaires.  

In this study, BIOD-105 and BIOD-107 demonstrated slightly more rapid absorption (as reflected by the mean time to 50% maximal insulin concentration), and markedly slower declines from peak effect than Humalog® with no significant differences among the three drugs regarding infusion site toleration.  The two Biodel formulations did not meet the company's target product profile and, therefore, will not be advanced into Phase 2 clinical testing.

Dr. Alan Krasner, Biodel's chief medical officer, stated: "These results are similar to what we observed in a previous Phase 1 study reported last month and indicate that we have achieved comparable tolerability to Humalog®, but they do not support further development of these candidates at this time."  

Dr. Errol De Souza, Biodel's president and chief executive officer, stated: "The findings from these studies have been instructive as we continue to pursue our ultra-rapid-acting prandial insulin development program.  Last month we reported our exciting data on the development of analog-ba
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
3. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
4. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
5. Biodel to Raise $9.4 Million Through Registered Direct Offering
6. Biodel Appoints Arthur Urciuoli to its Board of Directors
7. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
8. Biodel to Present at Upcoming Conferences
9. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjetaâ„¢
10. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
11. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... June 16, 2011 Reportlinker.com announces that a ... catalogue: UK CT Systems – ... http://www.reportlinker.com/p0555197/UK-CT-Systems-–-Market-Trend-Till-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Short Description ... data on the CT systems in UK. It ...
... Inc., a leading provider of software solutions to ... today announced that a number of pharmaceutical industry ... participate in the creation of a set of ... performance data. Each of the initial sponsors will ...
Cached Medicine Technology:Reportlinker Adds UK CT Systems - Market Trend Till 2016 2DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:7/31/2015)... New York, New York (PRWEB) , ... July 31, 2015 , ... ... started to strut their stuff, Super-Sod debuted their new type of sod called ... with registered trademark application in process. , To commemorate introduction of this new type ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by ... predictive health analytics , Jvion continues to disrupt the predictive analytic and ... that targets patient and population level illness to drive prevention and better health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... By Jenifer Goodwin HealthDay Reporter , ... that biomarkers in the blood may help diagnose Alzheimer,s ... better treatments. While there are currently no treatments ... disease, the hope is that being able to diagnose ...
... researchers from around the world will be in Milwaukee, ... gaining insights into the brain,s inner workings to better ... and how the brain is altered by neurological diseases ... 350 scientists will attend the Second International Conference on ...
... 13, 2010) - A protein crucial for the immune ... of a devastating form of childhood leukemia called T-cell acute ... the leukemic cells, the study shows, opening a potential avenue ... Led by Iannis Aifantis, PhD, associate professor of ...
... musty odors, along with visual evidence of blue-green algae, ... that harmful cyanotoxins are present in lakes or reservoirs. ... in Midwest lakes, taste-and-odor compounds were found almost every ... a warning that harmful toxins are present. "It ...
... paralysed found that their condition improved after they received a ... in the September issue of the European Journal of ... University in Cairo, Egypt, studied 60 patients with ischaemic stroke ... - who had been left with mild to moderate muscle ...
... Union, its incidence increased by almost 20%, from 2.1 million new ... issue [1] of the European Journal of Cancer (the ... prevention, published today (Monday 13 September). ... number of areas, says a paper by Dr. Jos M. Martin-Moreno ...
Cached Medicine News:Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 2Health News:Biomarkers May Aid in Early Diagnosis of Alzheimer's 3Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 2Health News:Leading brain scientists meet in Milwaukee to examine how to uncover the brain's secrets 3Health News:NYU Langone scientists find key pathway implicated in progression of childhood cancer 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Brain stimulation can help partially paralyzed stroke patients regain use of their muscles 2Health News:Cancer deaths fall, but prevention still lags behind 2Health News:Cancer deaths fall, but prevention still lags behind 3Health News:Cancer deaths fall, but prevention still lags behind 4Health News:Cancer deaths fall, but prevention still lags behind 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: